Low-dose naltrexone (LDN), a recently employed treatment for fibromyalgia due to its ability to reduce glial inflammatory response and upregulate opioid signaling by regulating Toll-like receptor 4 (TLR-4) and transient opioid receptor blockade. The gene discussed is TLR4; the disease is fibromyalgia.